Minakem-flap
Minakem-flap

Find Clinical Drug Pipeline Developments & Deals by Biocon Limited

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BCA101

            Therapeutic Area: Oncology Product Name: BCA101

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Recipient: Bicara Therapeutics

            Deal Size: $40.0 million Upfront Cash: Undisclosed

            Deal Type: Financing March 15, 2021

            Details:

            Bicara’s lead program, BCA101, a first-in-class EGFR / TGFβ-trap bifunctional antibody, entered a Phase 1/2 study at leading U.S. and Canadian cancer centers in July 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Insulin aspart

            Therapeutic Area: Endocrinology Product Name: Kixelle

            Highest Development Status: Approved Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 12, 2021

            Details:

            Kixelle, a fast-acting insulin analog indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above, has been approved as a 100 units/ml solution for injection in vial and pre-filled pen presentations.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rh-insulin

            Therapeutic Area: Endocrinology Product Name: Insugen

            Highest Development Status: Approved Product Type: Peptide

            Recipient: Christian Social Services Commission

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration December 15, 2020

            Details:

            The agreement is a part of Biocon's ‘Mission 10 cents’ program, wherein, it seeks to unlock universal access to quality insulins in low- and middle-income countries (LMICs) by making recombinant human insulin (rh-insulin) available for less than 10 U.S. cents per day.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Itolizumab

            Therapeutic Area: Immunology Product Name: EQ001

            Highest Development Status: Phase I Product Type: Large molecule

            Recipient: Equillium

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 04, 2020

            Details:

            Data will be presented demonstrating that modulation of the CD6-ALCAM pathway with itolizumab improves kidney and skin pathology in mouse models of SLE.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Itolizumab

            Therapeutic Area: Infections and Infectious Diseases Product Name: Alzumab

            Highest Development Status: Approved Product Type: Large molecule

            Recipient: Equillium

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 13, 2020

            Details:

            Biocon has received emergency use approval from Drugs Controller General of India for itolizumab in the treatment of CRS in COVID-19 patients with moderate to severe ARDS.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Itolizumab

            Therapeutic Area: Infections and Infectious Diseases Product Name: Alzumab

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 11, 2020

            Details:

            Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe COVID-19 complications.